(Q34253548)

31 July 2017

title

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies (English)

1 reference

31 July 2017

author

Mathias Witzens-Harig

object named as

Mathias Witzens-Harig

2

1 reference

ORCID Public Data File 2021

author name string

Sonia Vallet

1

1 reference

31 July 2017

Dirk Jaeger

3

1 reference

31 July 2017

Klaus Podar

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

13 February 2012

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

13

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

473-494

1 reference

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

The courage of one's convictions: the due diligence of Frances Oldham Kelsey at the FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Questions about gemcitabine dose rate: answered or unanswered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Stem cells hold their breath

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide in agnogenic and secondary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

A phase-2 trial of low-dose pomalidomide in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide and rituximab in Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Dose escalation of lenalidomide in relapsed or refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide therapy in a rare case of POEMS syndrome with kappa restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

POEMS syndrome with severe neurological damage clinically recovered with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Response: dexamethasone dose alters expression of NK activating receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

A Munc in the platelet granule works

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656091

10.1517/14656566.2012.656091

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference